AmorChem — Full Portfolio

12 tracked investments · listed companies and verified rows first

Inversagoinversago.comSeries A · Oct 2022 · $35Macquired by Novo Nordisk

Portfolio company acquired by Novo Nordisk for $1.1B USD.

Co-investorsGenesys Capital JDRF T1D Fund New Enterprise Associates (NEA)Tarnagulla Ventures adMare BioInnovations Amgen Ventures +2 more

Liminal Biosciencesliminalbiosciences.com in 𝕏

Liminal BioSciences, through subsidiary CALEDON BIOSCIENCE, discovers and develops small molecule therapeutics targeting G protein-coupled receptor pathways for metabolic, inflammatory, and fibrotic diseases.

AI & Machine LearningBiotechDigital HealthMedical DevicesBelleville, CA

Bruce(Chief Executive Officer)

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Atp SynthaseGiiant PharmaKallikreinNeurasicNod2Pex1SematheraSl2Srsf3Zipcodes En

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.